Business
Avidity Biosciences Appoints W. Michael Flanagan, Ph.D. as Chief Technical Officer
LA JOLLA, Calif., Jan. 21, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"LA JOLLA, Calif., Jan. 21, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of W. Michael Flanagan, Ph.D. as Chief Technical Officer. Dr. Flanagan will lead the early development strategy of Avidity's AOC programs as they advance to the clinic.\n\n \n \n \n \n \n \n\n \n\"Mike's deep understanding and execution of global drug development strategies for both RNA therapeutics and monoclonal antibodies will be invaluable as we transition to a clinical-stage company. Further, Mike will partner with our Chief Scientific Officer, Art Levin, to deepen the pipeline and broaden the AOC platform,\" said Sarah Boyce, President and Chief Executive Officer. \"We are eager to leverage Mike's extensive research and development expertise and I am pleased to welcome him to our leadership team.\"\nDr. Flanagan has extensive experience developing multiple therapeutic modalities, including RNA therapeutics, antibody drug conjugates, and bispecific antibodies. Prior to joining Avidity, Dr. Flanagan served as Senior Director and Project Team Leader, Oncology and Immunology for Genentech, Inc., where he advanced programs through late-stage research to end of Phase 2 development. Prior to Genentech, he served in roles of increasing responsibility in the biology groups at Sunesis Pharmaceuticals, Inc., Gilead Sciences, Inc., and Merck & Co., Inc. where he was Senior Director of RNA Sciences. Dr. Flanagan received a B.S. in Genetics from the University of California at Davis, a Ph.D. in Biological Sciences from the University of California at Irvine and was an American Cancer Society postdoctoral fellow at the Howard Hughes Medical Institute, Stanford University. \n\"Avidity is an amazing company and I'm thrilled to join such an outstanding team. Avidity's AOC technology is a transformative innovation in the field of RNA therapeutics, an area of particular focus for me over my career,\" said Dr. Flanagan. \"This is a great opportunity to help Avidity pioneer the next major class of RNA targeted therapies toward the clinic and to patients.\"\nAbout Avidity Biosciences\nAvidity Biosciences, Inc. is driven to change lives with a new class of therapies called Antibody Oligonucle...